Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-018-0347-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Venetoclax (VEN) is a medicine that helps treat a type of blood cancer called acute myeloid leukemia (AML) for patients who can't have intensive treatments.
- In a study comparing patients treated with VEN to those with other treatments, more VEN patients responded well (62% vs. 42%).
- The study suggests that using VEN helps these patients have longer periods without problems and might lead to better survival rates, making it a good option before a major transplant procedure.
Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
Leuk Lymphoma
December 2024
Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J) - Hematology and Stem Cell, Transplantation Unit - University of Bari 'Aldo Moro', Bari, Italy.
Despite the approval of new drugs, the inclusion of -omics-derived data and the integration of machine learning in both the diagnostic and therapeutic process, the prognosis of acute myeloid leukemia (AML) remains dismal. The curative path is still aimed at achieving a successful allogeneic hematopoietic stem cell transplant (HSCT) in most patients. Nevertheless, access to this procedure is limited to eligible patients.
View Article and Find Full Text PDFVenetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
J Clin Med
January 2024
Hematology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, 93000 Bobigny, France.
. Primary resistance of acute myeloid leukemia (AML) to the conventional 3 + 7 intensive chemotherapy and relapses after first-line chemotherapy are two highly challenging clinical scenarios. In these cases, when allogeneic stem cell transplantation is feasible, patients are usually retreated with other chemotherapeutic regimens, as transplantation is still considered, nowadays, the only curative option.
View Article and Find Full Text PDFComparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Value Health
December 2023
AbbVie Inc, North Chicago, IL, USA. Electronic address:
Article Synopsis
- - The network meta-analysis evaluated the effectiveness of combining venetoclax (VEN) with azacitidine (AZA) or low-dose cytarabine (LDAC) against other treatments and best supportive care for adults with untreated acute myeloid leukemia not eligible for intensive chemotherapy.
- - A systematic review identified five phase III trials comprising 1,140 patients, and the analysis showed that VEN + LDAC and VEN + AZA had the highest success rates for achieving complete remission and overall survival compared to other treatments.
- - The study concluded that both VEN + AZA and VEN + LDAC significantly outperformed monotherapies, suggesting these combinations should be prioritized for treatment-naive patients in this specific leukemia population.
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.
Blood Adv
July 2023
Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Although venetoclax-based lower-intensity regimens have greatly improved outcomes for older adults with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy, the optimal induction for older patients with newly diagnosed AML who are suitable candidates for hematopoietic stem cell transplant (HSCT) is controversial. We retrospectively analyzed the post HSCT outcomes of 127 patients ≥60 years of age who received induction therapy at our institution with intensive chemotherapy (IC; n = 44), lower-intensity therapy (LIT) without venetoclax (n = 29), or LIT with venetoclax (n = 54) and who underwent allogeneic HSCT in the first remission. The 2-year relapse-free survival (RFS) was 60% with LIT with venetoclax vs 54% with IC, and 41% with LIT without venetoclax; the 2-year overall survival (OS) was 72% LIT with venetoclax vs 58% with IC, and 41% with LIT without venetoclax.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!